Antares Pharma, a specialty pharmaceutical company, has received the Food and Drug Administration’s approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.
“The FDA approval of Tlando brings to market an oral formulation of testosterone that we believe will prove beneficial to physicians and their patients,” Robert Apple, president and CEO of Antares Pharma said.
Apple continued, “We have recently expanded our commercial organization to 108 sales representatives and expect to leverage our relationships with urologists and endocrinologists to drive adoption of Tlando. This approval also reinforces the opportunity for Antares to continue to drive share gains in the TRT market with both Tlando and Xyosted and support our future growth with an expanded commercial portfolio. We look forward to launching Tlando commercially, which will provide a complementary treatment option to patients and clinicians in the second quarter of this year.”
“We are excited with the opportunity to commercialize Tlando and reinforce our commitment to the TRT market,” Joe Renda, senior vice president, commercial of Antares Pharma said.
Renda added, “Our existing commercial capabilities and presence in the market with Xyosted provide an important foundation for the potential commercial success of Tlando. With an expanded commercial footprint, we expect to continue to foster our strong physician relationships to support their patient-centric care and preference for different treatment options. We believe Tlando’s oral formulation and convenient dosing, which requires no titration, differentiates it from other treatment options. As we prepare for the commercial launch, we look forward to our sales representatives detailing a differentiated portfolio of products consisting of Xyosted, Tlando and Nocdurna that will continue to deliver solutions for improved patient care.”